Positive News SentimentPositive NewsNASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free VNDA Stock Alerts $3.89 +0.03 (+0.78%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.86▼$3.9250-Day Range$3.47▼$4.6152-Week Range$3.30▼$7.00Volume799,311 shsAverage Volume873,966 shsMarket Capitalization$223.83 millionP/E Ratio77.82Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Vanda Pharmaceuticals alerts: Email Address Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy5.50% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment1.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.01 to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector559th out of 939 stocksPharmaceutical Preparations Industry261st out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.50% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 7.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 3.3 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest8 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from $0.01 to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 77.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 77.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.21.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAMarch 28, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 16, 2024 | seekingalpha.comLongboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems LikelyMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAMarch 7, 2024 | finance.yahoo.comChairman of Vanda Pharmaceuticals Inc (VNDA) Sells SharesMarch 6, 2024 | markets.businessinsider.comVanda Pharmaceuticals Receives CRL From FDA On SNDA For HETLIOZ - Quick FactsMarch 6, 2024 | msn.comVanda drops as FDA rejects Hetlioz label expansionMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 6, 2024 | prnewswire.comVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaFebruary 17, 2024 | finance.yahoo.comVNDA Sep 2024 3.000 putFebruary 17, 2024 | finance.yahoo.comVNDA Sep 2024 3.000 callFebruary 15, 2024 | bizjournals.comD.C. bioetch pins hopes on 3 drug approvals as battles with FDA continueFebruary 14, 2024 | finance.yahoo.comJim Simons Adds Vanda Pharmaceuticals to Portfolio in Recent TradeFebruary 12, 2024 | seekingalpha.comVanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By CashFebruary 12, 2024 | finance.yahoo.comEarnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?February 10, 2024 | finance.yahoo.comNews Flash: Analysts Just Made A Sizeable Upgrade To Their Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) ForecastsFebruary 8, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 8, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2023 Earnings Call TranscriptFebruary 8, 2024 | finance.yahoo.comQ4 2023 Vanda Pharmaceuticals Inc Earnings CallFebruary 7, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc (VNDA) Faces Revenue Decline Amid Patent Challenges and Generic ...February 7, 2024 | finance.yahoo.comVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 6, 2024 | msn.comVanda Pharmaceuticals Shares HETLIOZ® FDA Review ProgressFebruary 5, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ in the Treatment of InsomniaFebruary 5, 2024 | msn.comVanda updates on FDA review for Hetlioz label expansionFebruary 5, 2024 | markets.businessinsider.comVanda Pharmaceuticals: FDA Identifies Deficiencies In Connection With SNDA For HETLIOZFebruary 5, 2024 | finance.yahoo.comVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees203Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.05 Trailing P/E Ratio77.82 Forward P/E Ratio389.00 P/E GrowthN/ANet Income$2.51 million Net Margins1.30% Pretax Margin3.29% Return on Equity0.46% Return on Assets0.39% Debt Debt-to-Equity RatioN/A Current Ratio4.94 Quick Ratio4.92 Sales & Book Value Annual Sales$192.64 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$9.47 per share Price / Book0.41Miscellaneous Outstanding Shares57,540,000Free Float53,107,000Market Cap$223.83 million OptionableOptionable Beta0.77 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 64)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Kevin Patrick Moran (Age 39)Senior VP, CFO & Treasurer Comp: $660.22kMr. Timothy Williams (Age 48)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 58)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Gunther Birznieks (Age 54)Senior Vice President of Business Development Comp: $690.83kMr. Scott L. HowellChief People OfficerMs. Elizabeth Van EveryHead of Corporate AffairsMore ExecutivesKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKRigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAGossamer BioNASDAQ:GOSSVerastemNASDAQ:VSTMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 19,205 shares on 3/11/2024Ownership: 6.006%Goldman Sachs Group Inc.Sold 1,211,363 shares on 3/1/2024Ownership: 0.802%GSA Capital Partners LLPBought 161,737 shares on 2/16/2024Ownership: 0.987%Public Employees Retirement System of OhioBought 46,300 shares on 2/16/2024Ownership: 0.212%Wolverine Trading LLCBought 11,101 shares on 2/15/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed in 2024? Vanda Pharmaceuticals' stock was trading at $4.22 at the beginning of 2024. Since then, VNDA shares have decreased by 7.8% and is now trading at $3.89. View the best growth stocks for 2024 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, February, 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. The biopharmaceutical company earned $45.27 million during the quarter, compared to the consensus estimate of $37 million. Vanda Pharmaceuticals had a net margin of 1.30% and a trailing twelve-month return on equity of 0.46%. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE), What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.01%), Vanguard Group Inc. (6.01%), Dimensional Fund Advisors LP (3.42%), Nantahala Capital Management LLC (1.76%), Federated Hermes Inc. (1.42%) and GSA Capital Partners LLP (0.99%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VNDA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.